Ghost Tree Capital’s Acadia Pharmaceuticals ACAD Stock Holding History

Ghost Tree Capital’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-200,000	Closed	-$3.7M	–	64
2024 Q1	$3.7M	Buy	+200,000	New	+$4.96M	1.02%	33
2018 Q4	–	Sell	-500,000	Closed	-$10.4M	–	41
2018 Q3	$10.4M	Buy	+500,000	New	+$7.87M	2.21%	15
2017 Q4	–	Sell	-109,000	Closed	-$4.11M	–	50
2017 Q3	$4.11M	Buy	+109,000	New	+$3.55M	0.87%	41
2017 Q1	–	Sell	-350,000	Closed	-$10.1M	–	67
2016 Q4	$10.1M	Buy	+350,000	New	+$9.26M	2.43%	11

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Ghost Tree Capital's ACAD Position: Q3 2024 in Review

Ghost Tree Capital sold out of Acadia Pharmaceuticals (ACAD) in Q3 2024, closing a stake of 225,000 shares — an estimated $3.66M sold.

Ghost Tree Capital first reported a position in ACAD in Q1 2015 and held it in 18 quarters. The position peaked at $24.2M in Q1 2019. 256 funds tracked by Wall St. Rank hold ACAD as of Q3 2024.

Ghost Tree Capital reported no remaining Acadia Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Ghost Tree Capital sold 225,000 Acadia Pharmaceuticals shares in Q3 2024, an estimated $3.66M.
Ghost Tree Capital first reported a position in Acadia Pharmaceuticals in Q1 2015 and held it in 18 quarters.
Ghost Tree Capital's Acadia Pharmaceuticals position peaked at $24.2M in Q1 2019.
256 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2024.

Based on Ghost Tree Capital's 13F filing for Q3 2024, filed 14 Nov 2024.